Literature DB >> 27863258

Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing.

Jonathan A Nowak1, Matthew B Yurgelun2, Jacqueline L Bruce1, Vanesa Rojas-Rudilla1, Dimity L Hall1, Priyanka Shivdasani1, Elizabeth P Garcia1, Agoston T Agoston1, Amitabh Srivastava1, Shuji Ogino3, Frank C Kuo1, Neal I Lindeman1, Fei Dong4.   

Abstract

Mismatch repair protein deficiency (MMR-D) and high microsatellite instability (MSI-H) are features of Lynch syndrome-associated colorectal carcinomas and have implications in clinical management. We evaluate the ability of a targeted next-generation sequencing panel to detect MMR-D and MSI-H based on mutational phenotype. Using a criterion of >40 total mutations per megabase or >5 single-base insertion or deletion mutations in repeats per megabase, sequencing achieves 92% sensitivity and 100% specificity for MMR-D by immunohistochemistry in a training cohort of 149 colorectal carcinomas and 91% sensitivity and 98% specificity for MMR-D in a validation cohort of 94 additional colorectal carcinomas. False-negative samples are attributable to tumor heterogeneity, and next-generation sequencing results are concordant with analysis of microsatellite loci by PCR. In a subset of 95 carcinomas with microsatellite analysis, sequencing achieves 100% sensitivity and 99% specificity for MSI-H in the combined training and validation set. False-positive results for MMR-D and MSI-H are attributable to ultramutated cancers with POLE mutations, which are confirmed by direct sequencing of the POLE gene and are detected by mutational signature analysis. These findings provide a framework for a targeted tumor sequencing panel to accurately detect MMR-D and MSI-H in colorectal carcinomas.
Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27863258      PMCID: PMC5225299          DOI: 10.1016/j.jmoldx.2016.07.010

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  20 in total

1.  Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

Authors:  Laura E MacConaill; Elizabeth Garcia; Priyanka Shivdasani; Matthew Ducar; Ravali Adusumilli; Marc Breneiser; Mark Byrne; Lawrence Chung; Jodie Conneely; Lauren Crosby; Levi A Garraway; Xin Gong; William C Hahn; Charlie Hatton; Philip W Kantoff; Michael Kluk; Frank Kuo; Yonghui Jia; Ruchi Joshi; Janina Longtine; Allison Manning; Emanuele Palescandolo; Nematullah Sharaf; Lynette Sholl; Paul van Hummelen; Jacqueline Wade; Bruce M Wollinson; Dimity Zepf; Barrett J Rollins; Neal I Lindeman
Journal:  J Mol Diagn       Date:  2014-08-23       Impact factor: 5.568

Review 2.  Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer.

Authors:  Francis M Giardiello; John I Allen; Jennifer E Axilbund; C Richard Boland; Carol A Burke; Randall W Burt; James M Church; Jason A Dominitz; David A Johnson; Tonya Kaltenbach; Theodore R Levin; David A Lieberman; Douglas J Robertson; Sapna Syngal; Douglas K Rex
Journal:  Gastroenterology       Date:  2014-08       Impact factor: 22.682

3.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Authors:  Nicolas J Llosa; Michael Cruise; Ada Tam; Elizabeth C Wicks; Elizabeth M Hechenbleikner; Janis M Taube; Richard L Blosser; Hongni Fan; Hao Wang; Brandon S Luber; Ming Zhang; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Cynthia L Sears; Robert A Anders; Drew M Pardoll; Franck Housseau
Journal:  Cancer Discov       Date:  2014-10-30       Impact factor: 39.397

4.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

Review 5.  Milestones of Lynch syndrome: 1895-2015.

Authors:  Henry T Lynch; Carrie L Snyder; Trudy G Shaw; Christopher D Heinen; Megan P Hitchins
Journal:  Nat Rev Cancer       Date:  2015-02-12       Impact factor: 60.716

6.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.

Authors:  Beifang Niu; Kai Ye; Qunyuan Zhang; Charles Lu; Mingchao Xie; Michael D McLellan; Michael C Wendl; Li Ding
Journal:  Bioinformatics       Date:  2013-12-25       Impact factor: 6.937

7.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

8.  Applicability of next generation sequencing technology in microsatellite instability testing.

Authors:  Chun Gan; Clare Love; Victoria Beshay; Finlay Macrae; Stephen Fox; Paul Waring; Graham Taylor
Journal:  Genes (Basel)       Date:  2015-02-12       Impact factor: 4.096

9.  Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.

Authors:  Paul Lochhead; Aya Kuchiba; Yu Imamura; Xiaoyun Liao; Mai Yamauchi; Reiko Nishihara; Zhi Rong Qian; Teppei Morikawa; Jeanne Shen; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  J Natl Cancer Inst       Date:  2013-07-22       Impact factor: 13.506

10.  MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations.

Authors:  Mi Ni Huang; John R McPherson; Ioana Cutcutache; Bin Tean Teh; Patrick Tan; Steven G Rozen
Journal:  Sci Rep       Date:  2015-08-26       Impact factor: 4.379

View more
  43 in total

1.  Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma.

Authors:  Amin H Nassar; Kevin Lundgren; Jaegil Kim; Toni K Choueiri; Guru P Sonpavde; David J Kwiatkowski; Joaquim Bellmunt
Journal:  JCO Precis Oncol       Date:  2018-07-24

2.  Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.

Authors:  Glenn J Hanna; Alec Kacew; Nicole G Chau; Priyanka Shivdasani; Jochen H Lorch; Ravindra Uppaluri; Robert I Haddad; Laura E MacConaill
Journal:  JCI Insight       Date:  2018-09-06

3.  Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.

Authors:  Mohamed E Salem; J Nicholas Bodor; Alberto Puccini; Joanne Xiu; Richard M Goldberg; Axel Grothey; W Michael Korn; Anthony F Shields; William M Worrilow; Edward S Kim; Heinz-Josef Lenz; John L Marshall; Michael J Hall
Journal:  Int J Cancer       Date:  2020-06-18       Impact factor: 7.396

4.  Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.

Authors:  Heather Hampel; Rachel Pearlman; Mallory Beightol; Weiqiang Zhao; Daniel Jones; Wendy L Frankel; Paul J Goodfellow; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Angela Jacobson; Electra Paskett; Peter G Shields; Richard M Goldberg; Albert de la Chapelle; Brian H Shirts; Colin C Pritchard
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

Review 5.  Mismatch repair-based stratification for immune checkpoint blockade therapy.

Authors:  Lihong Zhang; Yang Peng; Guang Peng
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

6.  Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

Authors:  Glenn J Hanna; Patrick Lizotte; Megan Cavanaugh; Frank C Kuo; Priyanka Shivdasani; Alexander Frieden; Nicole G Chau; Jonathan D Schoenfeld; Jochen H Lorch; Ravindra Uppaluri; Laura E MacConaill; Robert I Haddad
Journal:  JCI Insight       Date:  2018-02-22

7.  A Canadian guideline on the use of next-generation sequencing in oncology.

Authors:  S Yip; A Christofides; S Banerji; M R Downes; I Izevbaye; B Lo; A MacMillan; J McCuaig; T Stockley; G M Yousef; A Spatz
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

8.  A robust method for the rapid detection of microsatellite instability in colorectal cancer.

Authors:  Lin Zhao; Guangyu Shan; Lei Li; Yang Yu; Gang Cheng; Xu Zheng
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

Review 9.  Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

Authors:  Larissa V Furtado; Wade S Samowitz
Journal:  Virchows Arch       Date:  2017-05-27       Impact factor: 4.064

Review 10.  Current and emerging biomarkers in metastatic colorectal cancer.

Authors:  M K C Lee; J M Loree
Journal:  Curr Oncol       Date:  2019-11-01       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.